Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8615975 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 21 Pages |
Abstract
Patients with BCR-ABL transcripts e14a2 transcripts have higher rates of CCR at 6 months and higher rates of optimal molecular response at 3 months compared with e13a2 or with both transcripts, but no difference in 5-year overall, progression-free, and event-free survival. There was a superior 10-year overall survival among patients with transcripts e13a2 compared with e14a2 (alone or coexpressed with e13a2).
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Katia Borgia Barbosa Pagnano, Eliana Cristina Miranda, Márcia Torresan Delamain, Gislaine Oliveira Duarte, Erich Vinicius de Paula, Irene Lorand-Metze, Carmino Antonio de Souza,